Unknown

Dataset Information

0

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.


ABSTRACT: Bosutinib is an oral, selective Src/Abl tyrosine kinase inhibitor with activity in breast cancer (BC). We evaluated bosutinib plus exemestane as second-line therapy in previously treated hormone receptor-positive (HR+) locally advanced or metastatic BC.This was a phase II study with patients enrolled in a single-arm safety lead-in phase. Patients receiving bosutinib at 400 mg or 300 mg/day (based on toxicity) plus exemestane at 25 mg/day were monitored for adverse events (AEs) and dose-limiting toxicities for 28 days, and initial efficacy was assessed. After the lead-in and dose-determination phase, randomized evaluation of combination therapy versus exemestane was planned.Thirty-nine of 42 patients (93%) experienced treatment-related AEs including diarrhea in 28 (67%) and hepatotoxicity in 11 (26%); overall serious treatment-related AEs were recorded in 4 (10%). No liver toxicity met Hy's law criteria. Dose-limiting toxicities occurred in 5 of 13 patients receiving 400 mg (38%) and 3 of 26 patients receiving 300 mg (12%) of bosutinib; all resolved on treatment discontinuation. One patient (300 mg/day) achieved confirmed partial response; three (400 mg/day, n = 2; 300 mg/day, n = 1) maintained stable disease for >24 weeks; a best response of progressive disease occurred in 15 of 42 patients (36%). Median progression-free survival was 12.3 weeks (80% confidence interval: 11.0-15.6).The risk-benefit profile of bosutinib at 300 mg/day plus exemestane resulted in early study termination before the randomized portion. Alternative bosutinib regimens merit investigation in BC.

SUBMITTER: Moy B 

PROVIDER: S-EPMC3983831 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy Beverly B   Neven Patrick P   Lebrun Fabienne F   Bellet Meritxell M   Xu Binghe B   Sarosiek Tomasz T   Chow Louis L   Goss Paul P   Zacharchuk Charles C   Leip Eric E   Turnbull Kathleen K   Bardy-Bouxin Nathalie N   Duvillié Ladan L   Láng István I  

The oncologist 20140327 4


<h4>Background</h4>Bosutinib is an oral, selective Src/Abl tyrosine kinase inhibitor with activity in breast cancer (BC). We evaluated bosutinib plus exemestane as second-line therapy in previously treated hormone receptor-positive (HR+) locally advanced or metastatic BC.<h4>Methods</h4>This was a phase II study with patients enrolled in a single-arm safety lead-in phase. Patients receiving bosutinib at 400 mg or 300 mg/day (based on toxicity) plus exemestane at 25 mg/day were monitored for adve  ...[more]

Similar Datasets

| S-EPMC3983830 | biostudies-literature
| S-EPMC8474426 | biostudies-literature
| S-EPMC3536885 | biostudies-literature
| S-EPMC10102835 | biostudies-literature
| S-EPMC7444639 | biostudies-literature
| S-EPMC7811234 | biostudies-literature
| S-EPMC7335268 | biostudies-literature
| S-EPMC10258741 | biostudies-literature
| S-EPMC4881332 | biostudies-literature
| S-EPMC7844919 | biostudies-literature